Exagen Inc. (NASDAQ:XGN) Short Interest Up 48.7% in October

Exagen Inc. (NASDAQ:XGN) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 23,500 shares, an increase of 48.7% from the September 30th total of 15,800 shares. Based on an average daily trading volume, of 53,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.3% of the company’s shares are short sold.

Exagen Stock Down 5.3 %

Shares of NASDAQ XGN opened at $2.69 on Monday. Exagen has a 12 month low of $1.30 and a 12 month high of $3.71. The company has a current ratio of 4.32, a quick ratio of 4.32 and a debt-to-equity ratio of 1.13. The company has a 50-day simple moving average of $2.94 and a 200-day simple moving average of $2.27.

Exagen (NASDAQ:XGN) last released its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.20. Exagen had a negative net margin of 30.56% and a negative return on equity of 78.90%. The business had revenue of $15.06 million for the quarter, compared to analysts’ expectations of $13.20 million. During the same period last year, the company earned ($0.28) earnings per share. Sell-side analysts anticipate that Exagen will post -1.02 earnings per share for the current year.

Institutional Investors Weigh In On Exagen

An institutional investor recently bought a new position in Exagen stock. Creative Planning bought a new position in Exagen Inc. (NASDAQ:XGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 35,500 shares of the company’s stock, valued at approximately $110,000. Creative Planning owned about 0.20% of Exagen as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).